HPV immunization coverage estimates among primary target cohort (9-14) in Singapore
Singapore: HPV immunization coverage estimates among primary target cohort (9-14) was 78.0% in 2025. ◆ Volatile
HPV immunization coverage estimates among primary target cohort (9-14) in Singapore, 2012–2025
Source: World Health Organization, Global Health Observatory.
Analysis
The most recent figure for hpv immunization coverage estimates among primary target cohort (9-14) in Singapore is 78.0%, measured in 2025.
That represents a change of up 7,700.0% over ten years.
Over the whole period, hpv immunization coverage estimates among primary target cohort (9-14) in Singapore peaked at 89.0% in 2020 and was at its lowest, 1.0%, in 2012.
That places Singapore 43rd out of 111 countries with data for 2025, putting it in the middle of the range.
The series is highly variable year to year, so single readings are best treated with caution.
HPV immunization coverage estimates among primary target cohort (9-14) in Singapore, year by year
| Year | Value | Change |
|---|---|---|
| 2012 | 1.0% | — |
| 2013 | 1.0% | +0.0% |
| 2014 | 2.0% | +100.0% |
| 2015 | 1.0% | -50.0% |
| 2016 | 1.0% | +0.0% |
| 2017 | 2.0% | +100.0% |
| 2018 | 39.0% | +1850.0% |
| 2019 | 75.0% | +92.3% |
| 2020 | 89.0% | +18.7% |
| 2021 | 89.0% | +0.0% |
| 2022 | 74.0% | -16.9% |
| 2023 | 72.0% | -2.7% |
| 2024 | 78.0% | +8.3% |
| 2025 | 78.0% | +0.0% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 15.2% | 1.0% | 75.0% | 8 |
| 2020s | 80.0% | 72.0% | 89.0% | 6 |
Countries ranked near Singapore
- 41 South Africa 79.0% compare
- 41 Solomon Islands 79.0% compare
- 43 Uruguay 78.0% compare
- 43 Tuvalu 78.0% compare
- 46 Switzerland 77.0% compare
- 46 South Korea 77.0% compare
- 46 El Salvador 77.0% compare
More health data for Singapore
- Un projection of annual infant deaths, annual growth rate 0 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.5225 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,924 deaths per 1,000 people (2090)
- Number of infants who die before age 1 13 deaths (2100)
- Population ages 75-79, female, annual growth rate 11.59 % change on previous year (2025)
- Population ages 75-79, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 75-79, female, per capita 0.0147 units per person (2025)
- Population ages 75-79, male, annual growth rate 12.05 % change on previous year (2025)
- Population ages 75-79, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 75-79, male, per capita 0.0123 units per person (2025)
Frequently asked questions
- What is hpv immunization coverage estimates among primary target cohort (9-14) in Singapore?
- Hpv immunization coverage estimates among primary target cohort (9-14) in Singapore was 78.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest hpv immunization coverage estimates among primary target cohort (9-14) recorded in Singapore?
- The highest recorded value was 89.0% in 2020.
- What is the lowest hpv immunization coverage estimates among primary target cohort (9-14) recorded in Singapore?
- The lowest recorded value was 1.0% in 2012.
- How does Singapore rank for hpv immunization coverage estimates among primary target cohort (9-14)?
- Singapore ranks 43rd out of 111 countries with data for 2025.
- Is hpv immunization coverage estimates among primary target cohort (9-14) rising or falling in Singapore?
- Over the last ten years it is up 7,700.0%. The long-run trend across the full record is volatile.
- Where does this Singapore data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of HPV immunization coverage estimates among primary target cohort (9-14 years old girls) (%). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 14 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).